

NON-PROFIT U.S.
POSTAGE PAID
BARNES-JEWISH
HOSPITAL FOUNDATION
PERMIT NO. 800



Barnes-Jewish Hospital Foundation
1001 Highlands Plaza Drive West
Suite 140
St. Louis, MO 63110

Web Site Connects You to Help and Hope

Learning more about Barnes-Jewish Hospital Foundation and making a gift is easier than ever through the Foundation's Web site at www.givingbarnesjewish.org.

By visiting the Web site, you'll be able to:

- Make a gift instantly by credit card, or print out a gift form to mail.
- Learn more about our important projects we fund in research, technology, education, patient support and other areas — and see the difference your gifts make.
- Learn more about the Cancer Frontier Fund, our \$50 million initiative to accelerate cancer breakthroughs.
- See videos and read stories of hope about our patients and givers.
- Read articles from past issues of our publications.
- Learn more about becoming a Barnes-Jewish Hospital volunteer.



BARNES - JEWISH HOSPITAL FOUNDATION

GIVING


ISSUE 1 2010

CARE • HOPE • THANKS



Surviving
Pancreatic Cancer
Is Possible!

DEPARTMENTS



ABOUT THE COVER
Bev Sodemann is surviving pancreatic cancer thanks to breakthrough immunotherapy research and treatment by William Hawkins, MD, and his colleagues.

COVER PHOTO: TIM PARKER

CARE

- 2 New Faces of Giving**
illumination10 co-chairs Jim and Stacey Weddle.
- 4 Breast Health Outreach Program Impacts Breast Cancer Rates**
Rates fell with mammography and education.
- 6 Kranzle's Advocacy Work Leads to Nursing Award**
Susan Kraenzle, RN, named St. Louis Nurse of the Year.
- 8 The Gift That Couldn't Wait**
A family makes a generous choice when help is needed most.
- 10 Oncology Nurses Put the Passion in Patient Care**
For nurses who care for cancer patients, every day brings new joys and challenges.

HOPE

- 12 Kareem Abdul-Jabbar Hosts *illumination10* Gala**
Annual fundraiser supports innovative research at the Siteman Cancer Center.

- 16 The Face of Personalized Medicine**
Becky Lorts is participating in a clinical trial that uses chemotherapy with fewer side effects.
- 17 Boosting Hope and Survival in the Fight Against Pancreatic Cancer**
William Hawkins, MD, and his colleagues are studying vaccines that turn on the immune system to attack pancreatic cancer cells.
- 18 Defying the Odds, Sharing the Hope**
Bev Sodemann fought pancreatic cancer and won as she participates in an immune therapy study using vaccines.
- 20 Endometrial Cancer Research Support Pays Off in Significant Grant**
Ongoing research recognized and rewarded as it gets boost from National Cancer Institute.
- 23 Small World**
R. Sherburne Figenshau, MD, urologic surgeon, expands research into minimally invasive cancer surgery techniques as The Taylor Family and Ralph V. Clayman, MD, Minimally Invasive Urology Chair.

THANKS

- 24 The Healing Nature of Art**
Lloyd Kleine Harvey will display his intricate, organic art April 22 to June 25 in the Arts + Healthcare Gallery at Barnes-Jewish Hospital.
- 26 Ringing in a New Life After Cancer**
Lisa Facer, breast cancer survivor, made a charitable gift to BJH Foundation to ensure every cancer patient had the opportunity to ring a bell to celebrate the end of cancer treatment.

IN EVERY ISSUE

- 1 President's Message**
- 14 FUNDamentals**
Focus on Cancer Frontier Fund – help us change cancer care and cure around the world!
- 28 The Giving Back Page**
Foundation Board Member Bill Koman invites you join him at the next frontier in cancer care and cure.

BJHF GIVING

BJH FOUNDATION
BOARD CHAIRMAN
Kenneth B. Steinback

BJH PRESIDENT
Richard J. Liekweg

BJHF VICE PRESIDENT
Julia S. Ruvelson

BJHF BOARD OF DIRECTORS

William L. Basler
S. Bryan Cook
Thomas R. Corbett
Gene M. Diederich
John P. Dubinsky
Leon A. Felman
Roxanne H. Frank
Richard S. Glassman
Susan K. Goldberg
Keith B. Guller
Earle H. Harbison Jr.
Thomas J. Hillman
William F. Holekamp
Mark E. Hood
Franklin A. Jacobs
Douglas O. Kirberg
Lee C. Kling
William J. Koman
Edward J. Koplar

Robert D. Millstone
Sandra M. Moore
Frederick J. Oertli
Joseph E. Rechter
Steven C. Roberts
Sally H. Roth
Robert E. Saur
Steven F. Schankman
David Sherman III
Alvin J. Siteman
Peter A. Smith
Norma E. Stern
Tom Stern
Walter G. Stern
Joseph A. Stieven
Kenneth H. Suelthaus
Harvey N. Wallace
David A. Yawitz
Mark H. Zorensky

HONORARY DIRECTORS

Shirley W. Cohen
Andrew B. Craig III
Joy T. Dunkelman
Alyn V. Essman
Harvey A. Friedman
Robert E. Kresko
Lee M. Liberman
E. Stephens Rand
Herbert E. Rosenbaum, MD
Mahlon Rubin
Mary G. Zorensky

EX-OFFICIO

oChristine M. Anthony
Richard J. Liekweg
Julia S. Ruvelson
Patrick T. Stokes
Carole Thaw

FOUNDATION STAFF CONTACTS

David Sandler
Acting Director
of Development
314-362-3499
dhs1634@bjc.org

Noël Schiber
Donor Relations
Manager
314-286-0452
njs1769@bjc.org

Kristin Marino
Senior Foundation
and Donor Events
Coordinator
314-286-0602
kgm4029@bjc.org

Abby Hughes
Senior Marketing
and Public Relations
Coordinator
314-286-0442
aeh2249@bjc.org

MANAGING EDITOR
Joyce Romine

WRITING/EDITING
Joyce Romine
Noël Schiber
Scott Ragan

GRAPHIC DESIGN
Design Invasion

PHOTOGRAPHY
Tim Parker
Tim Mudrovic

If you no longer wish
to receive *Giving* or if
you have a change of
address, please call
314-286-0442 or e-mail
givingbarnesjewish@bjc.org

A MESSAGE FROM THE BARNES-JEWISH HOSPITAL PRESIDENT

Trust

Trust must never be taken for granted. We see this in the faces of patients and families who turn to Barnes-Jewish Hospital for guidance, for answers, for innovation, for healing or comfort, and for hope at their most vulnerable moments.

Each person who walks through our doors gives us the opportunity to exceed expectations. Each day, this unique gift inspires us to ask a critical question: How do we continue leading medicine forward without losing sight of the individuals who put their trust in us?

In this issue of *Giving*, we will share with you the many ways that we are achieving this delicate balance for patients at the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. You will meet researchers who are discovering new options for fighting challenging cancers. You will feel the compassion of the nurses who make their rounds on the oncology floors, and whose outreach is making progress in beating breast cancer. You will read about cancer survivors who are using their talent and experience to encourage those who are currently fighting the disease.

All of these stories are possible because of givers like you. Thanks to your generosity, we can transform ideas into better patient care, health and outcomes right now. But you also make it possible to “dream big.” As we enter the second year of pursuing our \$50 million goal for the



Rich Liekweg

The Cancer Frontier Fund and our entire cancer care spectrum are important parts of Barnes-Jewish Hospital's larger commitment to more personalized and patient-focused care.

Cancer Frontier Fund, I marvel at this community's generous response to our dream to help the Siteman Cancer Center accelerate the pace of cancer breakthroughs. Every gift to the Cancer Frontier Fund will enable physicians around the world to someday give patients exactly what they need to survive their cancer, or to stop it before it starts. What an amazing testament to the power of giving.

The Cancer Frontier Fund and our entire cancer care spectrum are important parts of Barnes-Jewish Hospital's larger commitment to more personalized and patient-focused care. And everything that the Barnes-Jewish Hospital Foundation supports through your giving is intended to help us create an exceptional patient care experience that will enhance our reputation as national leaders in medicine. Thank you for making this difference in people's lives by entrusting us with your gifts.

Sincerely,

A stylized, handwritten signature in dark ink, appearing to read "Rich".

Richard J. Liekweg

President, Barnes-Jewish Hospital &
Barnes-Jewish West County Hospital
Group President, BJC HealthCare

New Faces of GIVING

Illumination10 co-chairs Jim and Stacey Weddle

Jim Weddle is the managing partner of Edward Jones. Stacey Weddle is a mother, minister and breast cancer veteran. Together, they are proud parents of three grown children and first-time grandparents of baby Abigail. This dynamic duo is stepping up in 2010 to help the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine make the future better for their family and yours.

What inspired you to take a leadership role in the Barnes-Jewish Hospital Foundation's *illumination10* gala to benefit the Siteman Cancer Center?

Jim: When Steve Lipstein (President and CEO of BJC HealthCare) asked us to consider chairing the gala for the Siteman Cancer Center, it was an easy decision. The work that Siteman does is amazing. I lost both my grandmother and my mother to cancer, and Stacey's mom died from breast cancer. Whatever we can do to help Siteman change that outcome for other families is vitally important.

Stacey: It's personal for me. My breast cancer was a rare, slow-growing type and was caught early on a routine mammogram. This meant we had options for treatment and were able to beat it quickly. But I want everyone to have more options, regardless of their cancer type or stage.

Edward Jones is the presenting sponsor of *illumination10*. How does this event reflect the values of your company and its role in our community?

Jim: We take our responsibility to be a good community citizen very seriously. John Bachmann (Senior Partner) taught us all well in that regard. Our associates, leaders and partners are given time to volunteer with the organizations close to their hearts.

Edward Jones was also an original contributor to the establishment of the Siteman Cancer Center. We know firsthand from associates who have been treated at Siteman how fortunate we are to have this world-class resource right here — so our involvement in *illumination* to raise funding for research at Siteman can only make this community an even better place to live and work.



Illumination10 co-chairs Jim and Stacey Weddle (a breast cancer veteran) are determined to help other families beat cancer by supporting the Siteman Cancer Center.

“There isn’t a family or organization that hasn’t been touched by cancer. You don’t have to look very far.”

—Jim Weddle

What are your hopes for the success of *illumination10*?

Stacey: Jim and I hope to raise awareness of the Siteman Cancer Center, to encourage St. Louisans to learn more about Siteman's national leadership, to get them more involved and to be more financially supportive. All of us have an opportunity to make a tremendous difference by giving to the Siteman Cancer Center!

If a business associate, family member or friend asked you why he or she should support the Siteman Cancer Center, what would you say?

Jim: There isn't a family or organization that hasn't been touched by cancer. You don't have to look very far. But it's also breathtakingly expensive to fund the research needed to find the cancer markers that will bring us closer to better treatments and cures.

Stacey: We never know what the future holds. Any one of us may need the services of the Siteman Cancer Center. Wouldn't you want Siteman to continue offering the latest treatments? The best research? Supporting Siteman is the right thing to do.

In what other ways do you enjoy contributing to the quality of life in St. Louis?

Jim: I find it rewarding to serve as a Saint Louis Science Center Commissioner, as well as on other boards of organizations like Webster University that are embracing innovative ways to advance their missions. I was honored to chair the walk for the Juvenile Diabetes Research Foundation — a great organization doing important work — and I was able to help build new connections and raise awareness. And now I'm gearing up to serve as the 2010 campaign chair for The United Way of Greater St. Louis — another terrific organization that touches the lives of more than a million people in the greater St. Louis area.

Stacey: The most important thing to me is my family. In fact, I became involved with St. Louis Irish Arts because my children enjoyed performing in the group. Both of our boys were part of the 2004 World Champion Irish Band that brought the title back to the United States. Our middle child still teaches and plays that bodhrán drum and will soon travel to Shanghai to perform during the World's Fair.

It was through St. Louis Irish Arts that our children participated in the Congressional Award program for Young Americans, in which youth earn bronze, silver and gold medals for achieving personal goals in public service, personal development, physical fitness and exploration. I'm thrilled to serve on the board of the Missouri Congressional Award Council so that I can encourage involvement in the program. I've also been blessed to use my master's degree in counseling to help establish a Stephen Ministry for one-on-one crisis counseling at my church, and to create from it a "Timothy Ministry" for peer-to-peer teen counseling.

Besides having access to national leaders like Barnes-Jewish Hospital, Washington University School of Medicine and the Siteman Cancer Center for health care, what do you love the most about St. Louis?

Jim: I'm originally from Chicago, and Stacey is from Indianapolis. Things have changed a lot since we first came here in 1976 so that I could finish my MBA at Washington University, but St. Louis has always been an amazing city with outstanding educational opportunities at every level. The significant presence of higher education institutions raises the quality of life here. I'm pleased to say that all three of our children have attended college in St. Louis!

Stacey: We have one of the absolute gems in the country with Forest Park, and the Art Museum, Science Center, Zoo and History Museum. Then there's the Fox Theatre, the Repertory Theatre and the Saint Louis Symphony — what a great community!

Jim: Don't forget the sports teams!

Stacey: And St. Louis is a great place to raise a family. There are many ways to stay involved in community service here. We have been able to lead by example. Now our kids give back, too.



Breast Health Outreach Program Impacts Breast Cancer Rates

Susan Kraenzle, RN, and Mario Schootman, PhD, helped put the wheels in motion for broader mammography screening.

Soon after Mario Schootman, PhD, an epidemiologist, came to Washington University in 1999, he reviewed data from the Missouri Cancer Registry and noticed a disturbing trend among patients with breast cancer: from 1996 to 1998, women who were 50 and older were twice as likely to have late-stage breast cancer if they lived in certain ZIP codes in the northeastern part of St. Louis. Schootman, who is co-leader of the Prevention and Control Program at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, had identified a significant cancer cluster. This was the beginning of the Red Map Study.

As a result of these findings, the Breast Health Outreach Program at the Joanne Knight Breast Health Center at Siteman developed an initiative to change the statistics. Its goal: to help a greater number of medically underserved women get mammograms. Major support from the St. Louis Affiliate of Susan G. Komen for the Cure® made the vision a reality.

“Dr. Schootman’s study was a call to action,” says Susan Kraenzle, RN, manager of the Joanne Knight Breast Health Center. “It helped us develop a focus for our outreach program. As a result, we doubled the number of women we serve. We work closely with our partners in

local clinics and health departments who know the needs of the people they service.

“Many of the women we serve would not have a mammogram unless the doctor or nurse in their clinic explains to them how mammograms can save their lives. We help them get the care they otherwise couldn’t afford. No woman is denied services based on her ability to pay.”

In 2009, the outreach program provided mammogram screenings to more than 2,600 underserved women. Most were reached through the Siteman Cancer Center Mammography Van. But it’s the program’s

PHOTO: TIM PARKER

work beyond screening that makes it the largest outreach of its kind in Missouri.

“If a woman is suspected of having breast cancer through our screening, we offer her a full scope of services, including education, diagnosis and treatment,” Kraenzle says.

Making Mammography and Treatment More Accessible

Two years ago, Schootman reviewed the breast cancer rates in these “red map” areas again to see if mammography had impacted the numbers. It had. In 2008, the incidence of late-stage breast cancer in this population had normalized.

“This is most likely a result of the increased, more accessible mammograms,” Schootman says.

“Dr. Schootman’s study was a call to action...It helped us develop a focus for our outreach program. As a result, we doubled the number of women we serve.”

– Susan Kraenzle, RN

Kraenzle says the mammography van is integral to the outreach program’s efforts. “Our collaboration with the Federal Qualified Health Center in our area has helped us better reach underserved women. We bring the screening to where they live through the mammography van. This aspect of outreach is critical for patients who lack transportation or confidence to negotiate what can be a complicated health care setting.”

The Breast Health Outreach Program is a key component of Siteman’s Program for the Elimination of Cancer Disparities (PECaD). The program also works with the hospital’s Daylight Project, which provides services to women who are new to the United States and have limited English proficiency and a variety of cultural needs.

Another important component in outreach is the Breast Health Patient Navigation service for women who come to Siteman for further testing and treatment. Funding from the St. Louis Affiliate of Susan G. Komen for the Cure® supports patient care as well as Patient Navigation services.

Breast Health Navigators are trained lay people from the community who accompany women at Siteman through the anxiety of the diagnostic process when a screening mammogram reveals something suspicious. “Some of these women will be diagnosed with breast cancer, and our Navigators will be right beside them, smoothing out a difficult journey,” Kraenzle says. “This program helps make sure women continue all the way through the process, from suspicious mammogram findings to a resolution in care. Our Navigators communicate well at all levels and are very passionate about helping people.”

She continues: “Everyone in the Joanne Knight Breast Health Center has a passion for helping others. Our outreach patients are able to receive treatment from top doctors with state-of-the-art technology in a world-class facility. Being able to offer that to these patients is wonderful.”

Identifying New Areas for Outreach

Recently, Schootman and his colleagues expanded the focus of the Red Map Study and looked to see where else in Missouri women were more likely to develop breast cancer. Again, the map lit up over a particular region. In this case, it was in western and northern St. Charles County.

“We found in this area, from 2001 to 2004, women older than 50 were 25 percent more likely to develop breast cancer than other women around the state,” Schootman explains.

As a result, a “calling study” was begun early this year to determine the reason for the cancer cluster. Over a three-month period, people were randomly called in the area and asked questions about mammography use, breast cancer risk factors, demographics and more.

Schootman says that Komen St. Louis has been instrumental in his epidemiological research. “If not for the Komen Affiliate, we wouldn’t be able to generate the maps for the study or conduct telephone interviews or realize other funding. If we determine that low mammography use is the root of this breast cancer rate in St. Charles County, we have several avenues to reduce the rate. Mammography is one way to tackle the issue. It’s satisfying to help identify interventions that can make such a difference.”

A Dire Need for Support

Despite the important impact the Breast Health Outreach Program has made, Kraenzle admits the economy has made their work difficult. “It has been a tough year for us. The state’s funding program, Show Me Healthy Women, has significantly cut funding to our outreach program, and they advised us that funding will be flat for the next few years. We’ve never had to tell anyone we can’t take care of them, but we’re running out of patient care funds.”

She says other providers expect funding shortfalls, too. “People look to Siteman and Barnes-Jewish for care as a safety net for the medically underserved. But we’re juggling funds from mammogram to mammogram. We’ve never been in this dire a situation before, and the challenge will continue for

Kraenzle's Advocacy Work Leads to Nursing Award

Even before kindergarten, Susan Kraenzle, RN, knew she wanted to be a nurse and follow in her mother's footsteps.

She began her career caring for babies in the neonatal intensive care unit at St. Louis Children's Hospital. But a family move to Ste. Genevieve resulted in a new position as a nurse in women's health. "I believe I'm always put where I need to be," she says. "I saw a huge need for women's health in southern Missouri."



While she was living in Ste. Genevieve, she wrote her first grant after watching the Susan G. Komen St. Louis Race for the Cure® on television. The grant was for outreach to rural women. "The Komen organization soon called to tell me they had been waiting for a grant proposal to help rural women," Kraenzle says. "Helping to establish that program was a big reward."

A few years later, her ties to Barnes-Jewish Hospital led her back to St. Louis to become manager of the Joanne Knight Breast Health Center at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. Managing the Breast Health Outreach Program is one of her responsibilities.

Kraenzle's dedication to preventing breast cancer is personal. Her sister died from breast cancer when she was just 42 years old, leaving behind three young children.

Because of Kraenzle's patient advocacy to promote and improve quality cancer care and nurse advocacy, she was named the "St. Louis Nurse of the Year" by the Missouri Nurses Association (MONA), Third District, 2009.

"She's dedicated her life to advocating for patients, both as a staff nurse and as an advocate for women's health," says Florence Speer, RN, vice president of MONA, Third District. "I nominated her, and we chose her for her advocacy on behalf of underserved women not only in St. Louis city and County, but also around the Bootheel and Ste. Genevieve."

Through grants from Missouri's Show Me Healthy Women Program and the St. Louis Affiliate of Susan G. Komen for the Cure®, Kraenzle oversees programs providing breast screening at no cost to thousands of women in underserved communities.

"It's an honor every day to work with a tremendous group of people who allow us to care for women who otherwise would not be able to get this lifesaving care," Kraenzle says.

(continued from page 5)

the next three to four years. We're emptying all our buckets."

Now more than ever, charitable gifts to the Barnes-Jewish Hospital Foundation can make a lifesaving difference for the women served by the Breast Health Outreach Program. To learn more about supporting the program, please call 314-286-0600 or e-mail givingbarnesjewish@bjc.org.

Auxiliaries Merge to Create Strong, United Group of Volunteers

In a decision that will benefit countless patients of Barnes-Jewish Hospital, the auxiliaries of the former Barnes Hospital and Jewish Hospital, which have operated as separate chapters of the Barnes-Jewish Hospital Auxiliary since the hospitals merged in 1996, agreed in January 2010 to merge into one auxiliary.

“The merger of our two chapters brings together the collective energies of two dynamic organizations that can do even more to support the mission of Barnes-Jewish Hospital,” says Ruth Springer, auxiliary co-president. “We’re excited by our enhanced abilities as it relates to fundraising and support.”

The merged auxiliary is comprised of more than 1,400 members and has a combined legacy of donating more than \$20 million to the hospital, along with thousands of volunteer hours.

“We have an exciting slate of ongoing and new projects we’re evaluating, but we’re committed to supporting the programs both chapters have supported in the past,” says Susie Luten, auxiliary co-president. “As one chapter, we have tremendous opportunity and resources to help fulfill the health care needs of our community and to help advance the national leadership of Barnes-Jewish Hospital.”

The Parkview Chapter, formerly the Jewish Hospital Auxiliary, was established in 1952. The chapter has supported projects that advance patient care, including the Joanne Knight Breast Health Center, staffing of the radiation oncology waiting room at the Siteman Cancer Center, construction of Goldfarb Hall at Goldfarb School of Nursing at Barnes-Jewish College (co-sponsored with the Plaza Chapter), and an annual scholarship for students at Goldfarb School of Nursing.

The Plaza Chapter, formerly the Barnes Hospital Auxiliary, was established in 1953. The chapter has supported a variety of special patient care and educational needs, including Barnes Lodge — a home away from home for long-term patients and their families — the BESt high school summer pharmacy experience program and an annual scholarship for students at Goldfarb School of Nursing.



Left to right: Barnes-Jewish Hospital Foundation Vice President Julia Ruvelson, Auxiliary Co-Presidents Ruth Springer and Susie Luten, and Auxiliary member Chris Anthony.

“The merger of our two chapters brings together the collective energies of two dynamic organizations that can do even more to support the mission of Barnes-Jewish Hospital.”

—Ruth Springer,
Barnes-Jewish
Hospital Auxiliary
co-president

The Gift that Couldn't Wait

A Family Makes a Generous Choice When Help is Needed More than Ever

**Editor's note: The donors featured in this article have requested anonymity.*

They were a typical family, enjoying the fruits of life and their love for each other, when cancer struck.

Thrust into an unfamiliar world, the family soon began to share the shock, stress and fear familiar to all whose sole focus becomes fighting the disease. Yet this experience also brought clarity.

"Throughout my husband's treatment, I began to realize the depth of burdens that patients with cancer and their families face," the patient's wife says. "Our family also realized how lucky we were to have the means to bear these burdens. So many other families were not as fortunate. I'll always remember their faces."

For this family, there was not a happy ending. But from their grief arose determination. "We vowed to do anything we could do to better the lives of people with cancer," the patient's wife says.

Making Life Better for Everyone with Cancer

With no fanfare or desire for publicity, the family created a Barnes-Jewish Hospital Foundation fund in memory of the loved one they lost. They dedicated the fund to supporting needs that bring comfort or healing to cancer patients and their families at the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. These needs are often just out of reach for families because of cost.



Jim Hoerchler, LCSW, uses donor gifts to help patients receive services they couldn't normally afford so they can focus on treatment and healing.

The family also committed to replenishing the fund every year with an annual gift, and promised a major gift through a bequest. Barnes-Jewish Hospital's Case Management and Social Services Department put the family's fund to work immediately by covering the costs of wigs, walkers, rent, utilities, transportation, lodging, and medications — anything to keep cancer patients self-confident, mobile, relaxed, close to family and healthy.

This family's giving, along with many other generous gifts, have enabled Barnes-Jewish Hospital to reach out to many Siteman cancer patients and their families at their most vulnerable moments so that they could focus on the most important goal: getting well.

The Moment of Truth

Letters from the Foundation told the family of the patients blessed by their giving over the years. But when the economy plummeted in 2008, the family learned that severe challenges also lay ahead. The number of people needing help soared as patients lost jobs and health insurance, while the Barnes-Jewish Hospital Foundation was forced to reduce its traditional allocations for patient care and social services.

The family knew that help could not wait. In a spirit of amazing empathy, the family's lead donor decided to convert the intended bequest into an immediate gift of \$525,000 to the Barnes-Jewish Hospital Foundation in the summer of 2009.

“...Although many things compete for your attention in health care, the most important thing is the human being in front of you.”

— Jim Hoerschler, LCSW

“We cannot give enough thanks to this family and other Foundation donors to patient care funds,” says James H. Hoerschler, LCSW, who manages adjunctive therapies for Case Management and Social Services at Barnes-Jewish. “I know of no other hospital that is privileged to help patients the way we do at Barnes-Jewish Hospital.”

Helping the Human Being in Front of You

When Hoerschler thinks of the family who restructured their deferred gift so that more cancer patients can be helped now, he hopes they know the profound difference they’re making in people’s lives.

“It is such a wonderful feeling to help someone with something many of us can afford to take for granted,” Hoerschler says. “When you hand medicine to a patient and they thank you with tears in their eyes...well, it keeps you incredibly motivated. It reminds you that although many things compete for your attention in health care, the most important thing is the human being in front of you.”


For more information on the many ways that you can give to support these services and many others, please call David Sandler at 314-286-0599, e-mail givingbarnesjewish@bjc.org, or visit www.givingbarnesjewish.org.

Some of the People Whose Lives Were Touched by Cancer Patient Care and Social Service Funds

- Mrs. R., a self-employed woman from rural Missouri whose husband abandoned her and her daughter after Mrs. R was diagnosed with cervical cancer. Six weeks of paying to stay in St. Louis for daily radiation treatments, followed by four months of chemotherapy that left her too fatigued to work, depleted her savings. Your gifts enabled our hospital to give Mrs. R peace of mind and a safe home environment for healing by helping to pay for some of her utilities.
- Mr. W., a cancer patient who came to Siteman for his first round of treatments. When Mr. W's income proved to be insufficient for covering the cost of medication co-pays, your gifts enabled our hospital to help him with these so he could continue his cancer treatment without interruption.
- Mr. M., who traveled to Siteman from Kennett, Mo., for surgery to treat jaw cancer. After physicians detected another large tumor, they whisked Mr. M back to surgery. His family wanted to stay at his side after this unforeseen event, but struggled to afford this because of their extremely limited income. Your gifts enabled our hospital to cover a week of lodging for Mr. M's wife and daughter so they could be here to support him during his recovery.

Barnes-Jewish Hospital's Case Management and Social Work staff rely on the Barnes-Jewish Hospital Foundation's patient care and social services funds to help the most vulnerable in our community — the uninsured, the underinsured, and the unemployed — focus on treatment and healing instead of worrying about financial burdens during a hospital stay, extended treatment and recovery.

These funds support services that are unreimbursable, yet essential to positive patient outcomes. Gifts to the Foundation provide the funding as part of our hospital's community health mission. Every gift to patient care and social service funds is crucial to ensuring that we can continue offering these vital services. We thank all who give for this purpose.



Oncology Nurses Put the **Passion** in Patient Care

Some of the oncology nurses making a difference for patients every day.
Left to right: Misty Cheesman, RN; Chris Rimkus, RN; Jim Wischmeier, RN (standing); Kelly McKibben, RN; and Angie Holtgrave, RN.

Oncology nurses often care for the sickest of the sick, which can be stressful and emotionally difficult. But every nurse who works with cancer patients shares the common denominator of passionate care for patients, says Christine Rimkus, RN, an oncology clinical nurse specialist at the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

“As an oncology nurse, you’re usually working with specific patients for a long time and form relationships with them. I’m always humbled by what I learn and gain from my patients. The patients are what I enjoy most about my job.”

Rimkus didn’t begin her career wanting to work with cancer patients. “Now I wouldn’t think of going anywhere else,” she says. “The field of oncology tends to pick you. Oncology care is challenging, and there are always new things to learn. For example, three to five new drugs are released every year with varying routes of delivery. We have to be on top of that and learn everything about these new medications.”

Unifying the Team to Improve Care

Oncology nurses at Siteman receive extensive training beyond nursing school. After they become registered nurses, they can choose from numerous oncology classes as they further their skills. Nurses also must be trained to administer chemotherapy and infusion therapy.

Barnes-Jewish Hospital and Siteman oncology care spans five floors and includes gynecologic oncology, medical oncology, stem cell transplant, radiation oncology, inpatient nursing, a breast cancer outpatient area and the 24/7 Cancer Care Clinic. This level of care requires more than 300 oncology nurses.

To unify oncology nursing team care, Rimkus developed a Clinical Practice Review Committee nearly three years ago that represents nurses from all areas of oncology care.

The committee looked at best care practices and determined how they can best use these guidelines to improve patient care. “Since cancer patients generally navigate the whole system at Siteman and Barnes-Jewish, we’ve made sure all the same practice guidelines are in place across the spectrum,” Rimkus says. “Our goal is to make a big place seem smaller both for patients and for nurses.”

This effort also fosters better communication that results in more coordinated, seamless patient care. “We encourage inpatient and outpatient oncology nurses to know each other because we work with many of the same patients,” Rimkus says. “We’re kind of a tag team of oncology nurses.”

Preventing Compassion Fatigue

Oncology nurses often develop relationships with their patients because they see them so frequently. “It can be extremely hard on nurses when their patients die,” Rimkus says. “This can lead to stress, burnout and compassion fatigue that ultimately affects patient care. That’s why it’s important that we help these nurses through an intervention program.”

Compassion fatigue is a relatively new term described as the “cost of caring” for others in emotional pain.

The Barnes-Jewish Hospital Foundation recently funded a program that incorporates tools to reduce compassion fatigue and stress for oncology nurses. Staff members from Barnes-Jewish Hospital will be trained as facilitators to continue delivery of the program into the future.

Research has demonstrated a correlation between compassion fatigue and burnout and patient satisfaction. “Throughout their cancer treatment, patients need the nurse’s physical and emotional strength and empathy,” Rimkus says. “If a nurse is overwhelmed and disengages, the patient knows it. Intervention will help both patients and nurses.”

Supporting Education and Emotions of Oncology Nurses for Better Patient Care

Oncology nursing is demanding. Nurses must stay abreast of the latest treatments and must deal with the emotional stress that can occur when caring for very ill patients. The Barnes-Jewish Hospital Foundation helps with this through donor gifts in several areas.

For example, the Oncology Nurse Professional Development Fund supports education for oncology nurses, and oncology certification for clinical and advanced practice nurses. In the past year, this funding enabled nurses to attend professional meetings to learn more about solid tumors, stem cell transplant, palliative care and survivorship. Nurses who attended shared this education with their colleagues.

Several nurses were also able to present at national meetings. “Participation at these national meetings is a valuable opportunity to share knowledge and expands oncology nurses’ expertise by learning from other institutions,” says Chris Rimkus, RN, oncology clinical nurse specialist.

She adds that having more educated nurses translates to better patient care. “Today, patients have access to more information and are more knowledgeable than ever. Nurses usually spend more time with patients than doctors can, and patients often ask nurses questions. With continuing education, our nurses are able to answer many of these complex questions about the latest treatments.”

To give to oncology nurses, please call David Sandler at 314-286-0599, e-mail givingbarnesjewish@bjc.org or visit www.givingbarnesjewish.org.

A Night of Champions: Kareem Abdul-Jabbar

to Host *illumination10* gala

On May 15, hundreds of generous St. Louisans will “get their heads in the game” by joining host Kareem Abdul-Jabbar for the Barnes-Jewish Hospital Foundation’s *illumination10* gala to benefit the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

Since 1999, *illumination* has generated net funds of more than \$5.5 million to support the Siteman Cancer Center — the only National Cancer Institute Comprehensive Cancer Center within 240 miles of St. Louis — in the fight against cancer. Proceeds increased dramatically over the last three years as the gala shifted focus to funding specific innovation opportunities like the Koman Center for Cancer Bioinformatics, and proton beam research through the S. Lee Kling Endowed Chair in Radiation Oncology. The 2009 event alone netted more than \$1.4 million to launch the Barnes-Jewish Hospital Foundation’s Cancer Frontier Fund, a 10-year, \$50 million research initiative spearheaded by Bill and Amy Koman in partnership with the hospital.

“Our team is every person in St. Louis who wants to beat cancer,” says Julia Ruvelson, vice president of the Barnes-Jewish Hospital Foundation. “Our heroes are the people and patients of the Siteman Cancer Center. Our game plan is to accelerate breakthroughs by raising millions of dollars for the Cancer Frontier Fund!”

Every dollar raised through *illumination10* will permit the Cancer Frontier Fund to support innovative research at the Siteman Cancer Center, enabling physicians to treat cancer more effectively by personalizing a patient’s therapy based on the genetics or molecular makeup of his or her cancer.

Research that helped uncover and understand the genetic changes that cause chronic myeloid leukemia is a major factor in how Kareem Abdul-Jabbar is successfully living with the disease. He announced his diagnosis in November 2009. Today, the NBA’s all-time leading scorer and the person named by *TIME* magazine as “History’s Greatest Player” serves as special assistant coach of the Los Angeles Lakers. He also pursues his love of history as the author of six best-selling books on historical subjects. When Abdul-Jabbar is not writing and speaking around the world, he is helping numerous charities — especially those devoted to beating cancer.

“My grandfather died from colorectal cancer, my uncle died from colorectal cancer and my father almost died from colorectal cancer,” Abdul-Jabbar told CNN in November. “I think it’s possible for someone in my position to help save lives.”

“Kareem Abdul-Jabbar puts a very public face on how innovative research can help people continue to live with energy and passion, despite a cancer diagnosis,” Ruvelson says. “We are thrilled that he will join with us on May 15 to score game-winning shots against cancer by giving to the Cancer Frontier Fund to accelerate cancer breakthroughs.”



ILLUMINATION

A CELEBRATION OF LIFESAVING CANCER CURES

The Barnes-Jewish Hospital Foundation's Annual Benefit for the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Saturday, May 15, 2010

Chase Park Plaza

Presenting Sponsor:

Edward Jones
MAKING SENSE OF INVESTING®

Special Guest: Kareem Abdul-Jabbar

Co-chairs: Stacey and Jim Weddle

For more information, visit

www.illumination10.org, or call

Kristin Marino at 314-286-0602.

illumination10 Committee

Keith Alper	Jennifer & Tom Hillman	Mary & Joe Stieven
Kay & John Bachmann	Lee C. Kling	Dee & David Stokes
Crystal & John Beuerlein	Amy & Bill Koman	Shawn & Ken Suelthaus
Mary & Bob Ciapciak	Stacey & Rich Liekweg	Larry Thomas
Kim & Gene Diederich	Merry & Jim Mosbacher	Sheila & Dan Timm
Hazel & Arnold Donald	Casey & Bob O'Brien	Alicia & John Tlapak
Kim & Tim Eberlein, MD	Penny Pennington & Mike Fidler	Connie & Jim Tricarico
Madeleine Elkins & Harvey Wallace	Jeana & Buddy Reisinger	Gerry & Bob Virgil
Brad Frick	Julia Ruvelson	Lee Wielansky
Vicki & Doug Hill	Marilyn & Ken Steinback	Michelle & Grant Williams

What Have Past *illumination* Gifts Accomplished?

illumination09: Launched the Cancer Frontier Fund. See page 15 to learn about the first grants awarded from the fund in 2010.

illumination08: Helped to establish the S. Lee Kling Endowed Chair in Radiation Oncology to perpetually fund research in the Kling Center for Proton Therapy at the Siteman Cancer Center. Chairholder Jeff Bradley, MD, anticipates the Kling Center will open in late 2010 or early 2011 as the first single-vault proton therapy center in the country.

Proton radiotherapy allows physicians to target cancer cells with greater precision so they can increase radiation with minimal damage to healthy tissue. For the first time, patients will be able to remain in St. Louis for proton therapy and to benefit from its research applications. These include patients with highly challenging cancers of the brain, eye or spinal column; breast, lung or prostate cancer patients for whom conventional treatments have been exhausted; and children.

illumination07: Advanced two exciting areas of research. One project, led by Graham Colditz, MD, DrPH, of the Siteman Cancer Center, is working to adapt the *Your Disease Risk* Web site (www.yourdiseaserisk.org) to the primary care setting as a tool to help patients identify lifestyle changes that can reduce their risk of chronic diseases, including breast cancer.

Other projects, led by researchers under John DiPersio, MD, PhD, and the Koman Center for Cancer Bioinformatics, are linking genetic data, predictive data and demographic data to identify genetic mutations and biomarkers (biological indicators that predict how a patient will benefit from a treatment) that can be used to develop novel cancer therapies. In some cases, the research data is leading to new clinical trials. Cancers being explored include Hodgkin lymphoma and non-Hodgkin lymphoma, acute myeloid leukemia and multiple myeloma.



AN INITIATIVE OF THE BARNES-JEWISH HOSPITAL FOUNDATION

FUNDamentals

FOCUS ON THE CANCER FRONTIER FUND

You can help to unlock the mysteries of cancer genetics.

You can help to speed up the pace of turning discoveries into new tests, imaging technologies, drugs, vaccines or other therapies to help every patient survive his or her cancer...or to stop cancer before it starts.

You can help to change cancer care around the world.

And you can do it all right here in St. Louis by giving to the Cancer Frontier Fund.

Donors have given more than \$1.44 million to the Cancer Frontier Fund since the Barnes-Jewish Hospital Foundation launched the initiative in 2009. Every Cancer Frontier Fund dollar will be invested in innovative cancer research at the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

With its genetic sequencing capability, imaging technology and clinical research environment, the Siteman Cancer Center offers a unique capacity for discovery that is leading the way with more than \$165 million in annual cancer research and related training grants. But as resources shrink, federal and private research funders have been less likely to support novel projects that may lead to the next giant breakthrough.

“When you consider that more than \$100 billion has been spent on cancer research over the last 40 years with only a small change in the overall cancer death rate, I would say that the time is now to shift our resources to support transformative research,” says Julia Ruvelson, vice president of the Barnes-Jewish Hospital Foundation. “The Cancer Frontier Fund is designed to support the big new ideas needed to win the war against cancer. With your gifts to the Cancer Frontier Fund,

the Siteman Cancer Center will emerge as the leader among leaders, with unprecedented opportunities to save countless lives.”

Siteman’s work to uncover the genetic and molecular basis of cancer is already advancing “personalized medicine.” In this new medical frontier, more accurate diagnoses are combined with a growing body of data on how an individual’s genetic makeup affects their response to treatment. We can now direct targeted therapies and new treatments to give patients more options, better outcomes or even the chance to prevent the disease entirely.

Want to see how you can be part of the next great human frontier? Check out the video at www.givingbarnesjewish.org/giving/cancer.

“The Cancer Frontier Fund gives us the flexibility to study the newest ideas in areas with the greatest promise for innovation and impact, including genomics, imaging and community health so that we can utilize tomorrow’s technologies on patient care today,” says Timothy J. Eberlein, MD, Siteman Cancer Center director. “Our partnership with donors to the Cancer Frontier Fund will help to maximize the impact that our world-class researchers will be able to make on the care of our patients.”

To make a gift to the Cancer Frontier Fund, please call Julia Ruvelson at 314-286-0580, e-mail givingbarnesjewish@bjc.org or visit www.givingbarnesjewish.org.

First Awards Made to Washington University Researchers By the Cancer Frontier Fund in 2010

- **John DiPersio, MD, and Linda Eissenberg, PhD:** Funding for a groundbreaking clinical trial that will be the first to combine gene therapy for leukemia with PET scanning to improve outcomes. They aim to create a non-invasive diagnostic test for predicting which patients who receive genetically modified human T cells for fighting cancer will develop deadly graft-versus-host disease (caused by rejection of the newly transplanted cells) following treatment, and to establish criteria for when to administer a drug that will safely eliminate the T cells before graft-versus-host disease takes hold. Eissenberg also received general funding for her work with Dr. DiPersio in other gene therapy trials.
- **Gerald Linette, MD, PhD, and Beatriz Carreno, PhD:** Funding for a study to generate a more potent vaccine for patients with melanoma. In early results, it appears that half of the metastatic melanoma patients in the study are responding completely to the vaccine.
- **Craig Lockhart, MD:** Funding to continue a study of the impact of the thymidylate synthase gene on patients with advanced stomach and esophageal junction tumors to predict their response before beginning chemotherapy. In preliminary results, Dr. Lockhart – a Washington University medical oncologist who also leads Siteman’s Developmental Therapeutics Program – and his colleagues have more than doubled the treatment response rate by testing for the gene prior to treatment. Dr. Lockhart also received general funding for his work supervising individuals who help to expedite the development of new treatments through clinical trials.
- **Will Gillanders, MD:** Funding for a phase I clinical trial of an innovative and highly effective breast cancer vaccine developed by Dr. Gillanders and his colleagues. The vaccine targets mamoglobin-A, a gene that is predominantly observed in breast cancers. The Phase I trial is the first step of translating their findings into treatment. If the vaccine is found to produce minimal side effects, the trial will be expanded to a larger number of patients.
- **Robert Pufahl Jr., PhD:** General funding for Pufahl, a medical chemist who studies compounds (substances consisting of two or more chemical elements) that are likely to impact treatment of various types of cancer, an area that is receiving new emphasis at Siteman. His involvement is critical to discovering compounds for the development of innovative drugs that are more targeted and less toxic.
- **Data management for phase I and pilot studies in developmental therapeutics:** All data from these innovative clinical trials are collected and reviewed by Siteman’s Data Safety and Monitoring Committee, the Food and Drug Administration and other regulatory agencies, any of which can audit data at their discretion. The meticulous level of care needed to ensure data accuracy and confidentiality requires a tremendous amount of resources.

The Face of Personalized Medicine

Six years ago at age 32, Becky Lorts found a lump in her left breast. She opted to fight her cancer with chemotherapy, radiation and surgery to remove both breasts, and she came out clear.

Two years later, Lorts' cancer returned. It moved to her liver and then to her brain.

Brain surgery, more chemotherapy and more radiation followed. Yet even when her liver tumor grew slightly in 2009, this mother of two would not give up.

To Matthew Ellis, MB, BChir, PhD, this made Lorts a perfect candidate for an exciting clinical trial, written by Cynthia Ma, MD, PhD, and funded by the National Cancer Institute, for women with metastatic breast cancer.


"My trial is testing whether a certain drug will block communication between my tumor and the pathway that feeds it," Lorts says. "The hope is that my tumor will not grow, or that it will even decrease in size. It's a form of chemotherapy that is way less toxic than the standard chemotherapy that we could have chosen."

The research of Dr. Ellis, the Anheuser-Busch Chair in Medical Oncology at Barnes-Jewish Hospital and a co-investigator of Lorts' clinical trial, drew Lorts to him in the first place.

"His work is so in-depth that I trust him completely," she says. "He puts his heart and soul into finding a cure that works for every type of breast cancer. Of course, my family also adores him because he takes the time to talk with us every time I see him. I know that I'm a person to him."

The Barnes-Jewish Hospital Foundation's Cancer Frontier Fund exists so that Dr. Ellis, Dr. Ma and other Siteman Cancer Center researchers have funding to take leaps that could rapidly result in new ways for patients to beat cancer without horrendous side effects, or to live with cancer in good health.

"I'm in no pain, I teach, I take care of my family — I do everything I normally do," Lorts says. "Every new option that's discovered through innovative research is a step in the right direction for cancer patients like me. I am living with cancer, not dying from it."



Becky Lorts, who is participating in a clinical trial with a less toxic form of chemotherapy.

**"I am living with
cancer, not dying from it."**

— Becky Lorts



William Hawkins, MD, and his patient Bev Sodemann, a pancreatic cancer survivor. Gifts to the Barnes-Jewish Hospital Foundation are funding Dr. Hawkins' research into vaccines to treat pancreatic cancer.

Boosting Hope and Survival in the Fight Against Pancreatic Cancer

Pancreatic cancer was pushed to the forefront of the news last year when actor Patrick Swayze died from it. More than 35,000 other people in the United States also died from pancreatic cancer in 2009.

Pancreatic cancer is one of the most deadly cancers. Because the pancreas is tucked behind the stomach deep inside the body, routine physical exams rarely find early pancreatic tumors. In addition, patients often don't have symptoms until the cancer has spread to other organs. As a result, fewer than 5 percent of people survive pancreatic cancer beyond five years.

Pancreatic cancer cells are also known to be particularly stealthy and spread early in the disease stage.

"In other cancers, tumors usually have to be large before cancer cells spread to the lymph nodes and other organs," explains William Hawkins, MD, a Washington University gastrointestinal surgeon at Barnes-Jewish Hospital and the Siteman Cancer Center who specializes in this disease. "But with pancreatic cancer, even a 1-centimeter cancer can spread to the lymph nodes. Its tendency to spread quickly undetected is one reason why pancreatic cancer is so deadly."

In the rare 15 percent of cases where pancreatic cancer hasn't spread to other organs, patients may be candidates for surgery to remove the tumor. For this group, the survival rate increases to 20 percent.

Heeding the Call for Better Treatment Options

The National Cancer Institute has designated development of an effective treatment for pancreatic cancer one of its highest priorities. Thanks to research on immunotherapy being done by researchers like Dr. Hawkins, better treatment options are on the horizon.

The first step to better treatments has been identifying pancreatic tumors by a readily

detectable marker that shows promise as a basis for immune therapy against the cancer. The marker is mesothelin, a protein that may play an essential role in the development and growth of cancer. This makes it an ideal target for immune therapy.

Researchers found that immune cells taken from pancreatic cancer patients can be coaxed to target mesothelin.

“If we can turn on the immune system to attack cells that have mesothelin, that might become an important part of pancreatic cancer therapy,” says Dr. Hawkins, a principal investigator and co-author of a study on this topic recently published in *Clinical Cancer Research*. “Because mesothelin in pancreatic cells spurs tumor growth, loss of mesothelin could make cancer cells behave more like normal cells. That means even if immunotherapy only knocked out the mesothelin in pancreatic cancer cells instead of killing the cells, it could still be effective.”

Triggering an Internal War Against Cancer

One way to activate mesothelin-specific immune cells is through a vaccine, which would boost the immune response to mesothelin to target pancreatic cancer cells.

“We’ve got some cancers to cure. Donors’ gifts offer hope through research and new treatments to patients in St. Louis and beyond.”

— William Hawkins, MD

Dr. Hawkins is conducting a clinical study of an agent that may activate specific immune cells in pancreatic cancer patients. Additional research, funded by the Barnes-Jewish Hospital Foundation, includes testing vaccines that train the immune system to create antibodies to attack cancer cells, and testing methodologies to reduce cancer’s ability to suppress immune responses.

Dr. Hawkins says the next generation of treatment will combine immune stimulation with a vaccine. “We believe the best therapy is a three-pronged immunotherapy approach,” he says. “We’re building toward that now.”

David Linehan, MD, a Washington University gastrointestinal surgeon and researcher, is also focusing on research to impede cancer’s ability to turn down immune response, which prevents the immune system from attacking cancer cells.

“Our goal is to stimulate the immune system so it recognizes cancer cells as dangerous and gets revved up against them,” Dr. Hawkins says. “We hope to trigger the immune system to target the mesothelin in pancreatic cancer cells. The question is how do we present the molecule so the immune system is angry about it and mounts an immune response against it, but not against healthy cells?”

The immune system is a powerful weapon that can turn for or against the body, he explains. “In autoimmune diseases, the immune system can kill a kilogram of normal healthy tissue while leaving the rest intact. We must find the switch that will get the immune system to look at a cancer and attack it. This will open a new cadre of treatment that is less toxic and more effective.”

Putting the Puzzle Together

Dr. Hawkins notes pancreatic cancer researchers are using information from the Human Genome Project, mapped at the Washington University Genome Center, and are working with researchers on other cancers. “The goal is to translate this immunotherapy approach to other cancers, too, including



breast cancer. There is such a big effort on many fronts. It’s a huge jigsaw puzzle, and it will take time to put it all together.”

Dr. Hawkins is very optimistic about the future of pancreatic cancer treatment. “Five years ago, we didn’t have anything to treat this disease. But recently we’ve begun to accelerate progress, and we’ve seen our first increase in survival rates in 50 years. There’s more hope now than ever before.”

Gifts to the Foundation Bring a Life-Giving Return on Investment

Dr. Hawkins credits the Barnes-Jewish Hospital Foundation with helping researchers get to this point. “The Foundation is almost like a venture capitalist. Five years ago, I was a young guy with ideas who wanted to make a difference. The Foundation bet on my ideas and gave me the resources to get started with research. As a return on investment, I’ve hired five people in our lab and generated more than \$2 million more in research funding to attack pancreatic cancer. The Foundation’s investment has paid off.”

Despite the progress made in pancreatic cancer treatment, Dr. Hawkins says this is just the tip of the iceberg. “I still have a lot of work to do — we’ve got some cancers to cure. I see this not as a 5K but rather a marathon. Donors’ gifts mean so much because they offer hope through research and new treatments to patients in St. Louis and beyond.”

“When one person is helped, it ripples out to so many more people.”

– Bev Sodemann

Defying the Odds, Sharing the Hope

Bev Sodemann, 58, is living proof of how research brings hope to so many lives.

After severe stomach pain sent her to the hospital in September 2008, Sodemann was diagnosed with pancreatic cancer. This hard-to-detect, fast-spreading cancer often has a grim outcome. But not for Sodemann.

In 2010, she is busy substitute teaching, taking her grandchildren on adventures and traveling, as she continues to participate in a clinical study through the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

“The opportunity to participate in a clinical study was one of the reasons I chose to go to Siteman for treatment,” Sodemann says. “At first, I didn’t know anything about pancreatic cancer except that the outlook was grim for patients. My daughter did a lot of research about where I should go for treatment and looked at places around the country. We found Siteman was the best for pancreatic cancer care.”

Siteman has one of the highest-volume pancreatic cancer programs in the United States.

Her Decision to Help Advance Care

Sodemann’s first step in treatment was surgery. William Hawkins, MD, a Washington University gastrointestinal surgeon at Barnes-Jewish Hospital and Siteman who specializes in pancreatic cancer, performed a Whipple procedure, a complex operation that includes removing the head of the pancreas, the gallbladder, the common bile ducts, most of the duodenum and part of the stomach. Washington University surgeons have extensive experience in performing this procedure with extremely low rates of complications and mortality.

Sodemann qualified for a clinical study that included traditional chemotherapy along with a vaccine designed to stimulate the immune system to attack cancer cells. In January 2009, she began sixth months of chemotherapy complemented by the

vaccine. While her chemotherapy is now over, she will continue to receive the vaccine once a month for the next five years.

“I consider participating in the study as my safety net that keeps me well,” Sodemann says. “I feel so good right now. Joining the clinical study was a no-brainer for me. I decided to do it for every chance it gave me and because it will help others — and they could be my family members. Without clinical studies, doctors can’t make advances in care.”

“Every Day Is a Gift”

Surprisingly, Sodemann sees her experience with pancreatic cancer as a blessing and is now living life to the fullest. “It has allowed me to see so much good in the world,” she says. “I’ve written things down on paper that I want to do in life and am making sure I *do* them, rather than putting them off.”

At the top of her list is taking her daughter and grandchildren to Disneyland and Sea World this summer. She also plans to go to North Carolina to zipline, after white-water rafting there last summer. And in the fall, she’s planning a much-anticipated trip with her husband to Hawaii.

“I know statistically, pancreatic cancer can come back,” Sodemann says. “But Dr. Hawkins told me not to worry about statistics because all I have to be is the one to survive. That advice has stayed with me. So I’m not really worrying about cancer — it gets easier with each passing month. No matter what happens down the road, I’m grateful for all the time I have. Every day is a gift.”

Sodemann is pleased to help other people through her story of survival. “When people see me doing so well, it gives them hope,” she says. “That’s why I’m so appreciative of donor gifts that help fund research. When one person is helped, it ripples out to so many more people. Through gifts, we can make important strides in care.”

Endometrial Cancer Research Support Pays Off in Significant Grant

Success really does bring more success.

For 15 years, David Mutch, MD, a Washington University gynecologic oncologist at Barnes-Jewish Hospital, and Paul Goodfellow*, PhD, a Washington University geneticist, have collaborated on endometrial and ovarian cancer research. The Barnes-Jewish Hospital Foundation helped to advance their fruitful partnership, first through ongoing support from an endowment gift made by the late Dorothy J. Poetting, and most recently through a grant from the Foundation's Michael and Carol Staenberg Gynecologic Oncology Research Fund.

Now this team's research success has led to a significant three-year grant from the National Cancer Institute (NCI).

For the first time, the NCI has awarded a prestigious Specialized Programs of Research Excellence (SPORE) grant to researchers at the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. The grant funds research into the causes of endometrial cancer as well as strategies to prevent the disease and development of new treatments.

"A SPORE grant recognizes a specialized program of research excellence," Dr. Mutch says. "I truly appreciate the support of people like the Staenberg family and Mrs. Poetting, who laid the foundation so we could eventually receive a SPORE grant for our work in endometrial cancer."

The Barnes-Jewish Hospital Foundation and Washington University School of Medicine are each making \$750,000 contributions to meet the required institutional match for a SPORE grant.

"The Foundation can respond to elite opportunities to move medicine forward because so many generous people have given us flexible, unrestricted support," says Julia Ruvelson, vice president, Barnes-Jewish Hospital Foundation. "The amazing potential of the SPORE grant is a testament to the power of giving."

Strides Made in Inherited Endometrial Cancer

Endometrial cancer is the fourth most common cancer in American women. Every year, 40,000 cases of endometrial cancer are diagnosed, and more than 7,000 women die from the disease. Each year, both the incidence of endometrial cancer and its mortality increase.

Dr. Mutch and Goodfellow's partnership combines basic science and clinical research to directly benefit patients. The research team has identified certain abnormal molecules that lead to endometrial cancer.

In addition, the research team has identified a subgroup of women who are susceptible to endometrial cancer because of inherited or acquired mutations in their DNA repair genes. The discovery of the inherited mutations has led to changes in clinical care for these women and their

relatives, who are watched carefully for such signs of related malignancies such as colon, bladder or ovarian cancer.

The study has direct implications for St. Louis families. "By identifying genes, we went quickly from 'bench to bedside' with new therapeutic options," Dr. Mutch says. "For example, through our studies, we've identified many families in St. Louis that had an inherited form of endometrial cancer. If these families are screened regularly, their risk of colon cancer decreases."

Landmark Discoveries Lead to More Funding

The researchers' landmark discoveries identifying the genetic abnormalities that play a critical role in endometrial tumor development has contributed to Goodfellow and Dr. Mutch being recognized as national leaders in their fields. And this work caught the attention of SPORE reviewers. Dr. Mutch credits the support he and Goodfellow have received along the way that led to the SPORE.

"The Staenberg Fund and the Poetting Endowment Fund of the Barnes-Jewish Hospital Foundation were instrumental in our progress over the past two years," Dr. Mutch says. "The funding supported endometrial and ovarian cancer research while also allowing us to recruit and promote junior faculty to advance other studies, including those on ovarian cancer."

One of Goodfellow and Dr. Mutch's current research projects intends to determine the best way to screen patients with endometrial cancer for the genetic mutation that leads to the inherited form of the disease. "The goal is to ensure no one with hereditary cancer is missed," Dr. Mutch says. "We're focused on determining the most cost-effective and reliable approaches to screening that will translate to a reduction in cancer burden for the patient and her family."

One of Dr. Mutch's other goals is to develop more personalized cancer treatments. "If we've identified a genetic mutation, ideally we would have a specific drug treatment for that type of cancer versus another cancer. We're working toward that."

Dr. Mutch is excited about the possibilities brought by support such as the Poetting Endowment Fund, the Staenberg Fund and the SPORE grant. "Gifts and grants tend to have a snowball effect — more gets more. And we've been able to bring more to our research to quickly provide a direct benefit to patients."

*Goodfellow recently received the first "Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher." This annual prize is awarded to an individual in recognition of his or her outstanding contributions to research improving the care of women with gynecologic cancer.

Photos at right: top, Paul Goodfellow, PhD; bottom, David Mutch, MD.



“The amazing potential of the SPORE grant is a testament to the power of giving.”

— Julia Ruvelson, vice president, Barnes-Jewish Hospital Foundation



HOPE



PHOTO: TIM PARKER

Small World:

Newest Endowed Chair Holder is Minimizing Cancer Surgery to Maximize Patient Outcomes

When it comes to improving care for patients facing kidney, prostate or testicular cancer, Washington University and Siteman Cancer Center urologic surgeon R. Sherburne Figenshau, MD, thinks small — smaller incisions, smaller cuts and smaller amounts of time inside the body.

As the Taylor Family and Ralph V. Clayman, MD, Minimally Invasive Urology Chair, the impact of Dr. Figenshau's work will resonate around the world.

"I'm very humbled and excited to accept this endowed chair, and so deeply grateful for the generosity of Jack Taylor, the Taylor Family, Enterprise Rent-A-Car Foundation and other donors to the Barnes-Jewish Hospital Foundation," Dr. Figenshau says. "My team and I can now devote more time to research that will help us continue improving techniques for reducing the degree to which we have to invade the body to remove tumors.

"Each advance translates into shorter hospital stays, less pain and quicker recovery for our patients."

The namesake of the endowed chair, Ralph V. Clayman, MD, former Washington University professor of urology and radiology (and current dean of the University of California, Irvine School of Medicine), has been a mentor to Dr. Figenshau throughout his career.

"I met Dr. Clayman in 1981 when I worked in his laboratory at the University of Minnesota researching renal cancer," Dr. Figenshau says. "During medical school, he encouraged me to attend Washington University School of Medicine for my residency, where I had the good fortune to again be in his lab as he was

pioneering the laparoscopic kidney removal that revolutionized modern urological surgery. To hold a chair in his name is a very special honor."

Since completing residencies in general surgery and urologic surgery and joining the Washington University faculty in 1993, Dr. Figenshau has worked to expand minimally invasive surgical techniques for both adults and children. He is eager to explore new possibilities in kidney and testicular cancer treatment.

"We've gone from removing the entire kidney to removing only the cancerous part of the kidney, which has improved with the use of the da Vinci robot in kidney surgery," Dr. Figenshau says. "The robot gives the surgeon improved wrist action, enabling more precise cutting and more secure sutures. These improvements reduce surgical complications, such as urinary leakage and bleeding from the kidney."

The da Vinci® Surgical System is a computer-enhanced, minimally invasive surgical tool. The system was purchased in 2007 through the support of Barnes-Jewish Hospital Foundation donors. Surgeons at Barnes-Jewish conducted their 1,000th robotic surgery case using the da Vinci system in January 2010.

"I'd like to use the da Vinci robot to continue developing techniques that shorten the amount of time we must cut off the blood supply from the kidney during this procedure," Dr. Figenshau says. "This can minimize injury to the kidney and preserve as much of its function as possible, with better patient outcomes."

He says he would also like to apply the robot to a procedure called a retroperitoneal lymph node dissection, used for staging and treating testicular cancer. "This will change the operation from a procedure with a very large incision into a minimally invasive procedure. In fact, through the enhanced opportunities of my endowed chair, I hope to be instrumental in establishing minimally invasive techniques as the standard treatment of testicular cancer."

"Each advance translates into shorter hospital stays, less pain and quicker recovery for our patients."

—R. Sherburne Figenshau, MD
The Taylor Family and
Ralph V. Clayman, MD,
Minimally Invasive Urology Chair

As director of the Minimally Invasive Urology Fellowship Program, Dr. Figenshau looks forward to teaching the techniques he and his colleagues develop so this work will be applied more broadly, and even be enriched. "The residents keep me on my toes," he says. "Their questions always have me thinking of how to make things better."

He says he is grateful to work at Washington University and Barnes-Jewish Hospital. "The academic opportunities are outstanding, and the facilities maintained by Barnes-Jewish are world-class. It's a perfect blend for making patient care better — and gifts to the Barnes-Jewish Hospital Foundation are a great way to benefit patient care."

The Healing Nature

Lloyd Kleine Harvey, 77, grew up in St. Louis with a big sycamore tree adorning his front yard. He loved that tree, from the flaky texture of the mottled bark to the wide, veined leaves. This fascination and appreciation of nature became the root of the artwork he creates today.

From April 22 through June 25, 2010, Harvey's art will be displayed in the Arts + Healthcare Gallery in the Shoenberg Pavilion, adjacent to the Center for Advanced Medicine at Barnes-Jewish Hospital and Washington University School of Medicine. It's an opportunity that Arts + Healthcare Coordinator Sarah Colby has been hoping for since she met Harvey at the hospital last summer.

"Lloyd's experiences with the transformative possibilities of art and his marvelous ability to articulate that to a broad audience struck a chord," Colby says. "We felt an immediate kinship over the connection between art and healing. Sharing Lloyd's lovely and meaningful work in our gallery, which has become a place of respite and contemplation for many patients, families and caregivers in stressful situations, is perfect."

Expression Takes Root

While his lifetime work has spanned sculpture, painting and drawing, in recent years Harvey has transitioned into creating intricate, organic art from twigs. "I have such a reverence of trees from my early childhood. It's like returning to my roots.

From ancient times, trees have been symbols of spiritual growth."

You may see Harvey strolling through area parks as he searches for just the right leaves or twigs to use in his artwork. He intertwines twigs and branches to become one intricately woven piece. "They represent our interconnectedness," he says. "We are all one. And life is fragile. I do my best to reduce, reuse and recycle all of the material I use. I can easily and simply return to the earth."

Harvey is an extensively trained artist. He has studied at the Art Institute of Chicago, as well as the School of Visual Art and the Parsons School of Design in New York City. He also founded the Arte Ecologico de los Ninos in Oaxaca, Mexico, a



of Art

children's group that creates artwork that emphasizes recycling. In 1995, he returned to St. Louis and became the founder/director for Art from Recycled Materials in St. Louis.

Transforming Suffering

Harvey says he was recently inspired by a phrase from *Infamous*, a film about Truman Capote's work on *In Cold Blood*. Capote said: "I can alchemize what wounds me into art."

"It's about transforming suffering," Harvey says.

Harvey had a difficult childhood. The youngest of seven boys, he struggled to find his identity as racial tension permeated society. In college, he became a social activist. In 1952, he was drafted and served as a U.S. Army medic in the Korean War. Through the years, he has taught children

about art, cared for AIDS patients and become a steward for the earth.

Since he returned to St. Louis, Harvey has sought care at Barnes-Jewish Hospital for various health issues, including prostate cancer, heart bypass surgery and injuries he suffered after being struck by a car. Yet he has never thought of himself as a cancer patient. Or a heart patient. Or a victim. He is an artist on a journey.

The Power for Patients and Families

Harvey's life experiences have shaped the art he was destined to create. "Each of the weavings is a reflection in some way of my life and how relationships have woven their way throughout it," he says. "Through my art, I develop a stronger will to connect, to love, to let go of fear, to stay

in the now and to unlock the fullness of who I really am."

While those are his feelings, he doesn't pretend to know what patients and families may feel when they view his art.

He refers to a vision statement that he wrote for himself recently. "As my soul, my spirit continues to evolve, I see my art as a way of sending light into the darkness, serving as a meditative guide for others... My life, my art and my practice are all of one accord: to serve."

All exhibits in the Arts + Healthcare Gallery are free and open to the public. For more information on current exhibitions or the Arts + Healthcare program, contact Sarah Colby at 314-286-0592 or sjco705@bjc.org.

Ring in a New Life After Cancer

Because cancer runs in her family, 54-year-old Lisa Facer had always been diligent about getting annual mammograms. But in 2006, she missed her mammogram as she and her sister cared for her dying mother in Hawaii. In 2007, the company where she was a corporate bond trader was in turmoil — so she missed her mammogram again. In May 2008, Facer lost her job. So with time on her hands, she finally went for a mammogram. On D-Day — June 6 — she got the news she dreaded: breast cancer.

While she began her treatment elsewhere, within two weeks she was at the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

“I had HER2-positive breast cancer and needed to find someone who specialized in this,” Facer says. “So I went to the Siteman Web site and found Dr. Ron Bose. It was the best decision I made. Dr. Bose is not only an outstanding researcher and oncologist, but he truly cares about you as a patient and a person.”

Ron Bose, MD, PhD, is a Washington University medical oncologist at Siteman. He made Facer aware of a clinical trial for patients with HER2-positive breast cancer. “I’m a huge supporter of clinical trials so I was happy to participate,” Facer says. “There wouldn’t be new drugs without them.”

HER2-positive breast cancer is an aggressive form of breast cancer that stems from a gene mutation. It has a tendency to spread and to



Through a charitable gift to the Barnes-Jewish Hospital Foundation, breast cancer survivor Lisa Facer made sure patients at the Siteman Cancer Center can ring a bell to celebrate the end of their treatment.

recur. However, research is developing promising new drug combinations in the fight against this form of breast cancer.

Arts Program Creates An Important Friendship

Part of Facer's treatment included four-hour chemotherapy treatments, which she received at Siteman's satellite facility at Barnes-Jewish West County Hospital. During that time, Sarah Colby, program coordinator of the Arts + Healthcare program at Barnes-Jewish Hospital, began an arts program for cancer patients at the facility. The program is funded through the Barnes-Jewish Hospital Foundation.

“I rang the bell not just once but three times! It was a wonderful, liberating feeling.”

— Lisa Facer

“Art therapy has been such a godsend,” Facer says. “It gave me a reason to think about something other than cancer. All of the chemotherapy patients and family members would talk and laugh together while we did various art projects. We have developed a valuable support system through this program.”

It also launched a strong friendship between Facer and Colby that now impacts other cancer patients every day at Siteman.

The Bells of Siteman

On Dec. 19, 2008, Facer rang a bell at Siteman's west county facility signifying her last day of chemotherapy, continuing a celebratory tradition found in cancer centers around the country. “I rang the bell not just once but three times!” she says. “It was a wonderful, liberating feeling. You're so tired but you're still strong enough to ring the bell. Ringing the bell represents a huge step toward a new life.”

After she was done with chemotherapy, Facer faced radiation therapy five days a week at Siteman's campus at Barnes-Jewish Hospital. But when she completed her radiation treatment after nearly seven weeks, there was no bell to ring. She immediately set out to change that for all the patients who came behind her.

“I thought it was so important to have a bell in radiation oncology because radiation is a tough part of treatment,” Facer says. “I told Sarah I wanted to sponsor bells in honor of my parents who both died of cancer. Sarah recognized how important it was for cancer patients and took on the project with such persistence and tenacity. Sarah is a gift to Siteman and Barnes-Jewish Hospital. She is so wonderful with patients who have cancer.”

Thanks to Facer's charitable gift to the Barnes-Jewish Hospital Foundation and Colby's help, bells have been added in the radiation oncology area and the chemotherapy treatment area at the main Siteman facility, and in the radiation oncology area at the west county facility.

Knowing the bells are in place gives Facer great satisfaction.

“Recently, I was at the Siteman Cancer Center and heard the bell ringing from the radiation oncology department below,” Facer says. “It brought tears to my eyes because I knew just how that patient felt.”

With an unstoppable attitude and an infectious laugh, Facer enjoys making a difference in other patients' lives. She continues to volunteer at Siteman's west county facility in the chemotherapy area and in the arts program with Colby. She's also very active in other breast cancer events and projects through Siteman.

“Life is in the living,” she says.



THE GIVING BACK PAGE

By Bill Koman, Director,
Barnes-Jewish Hospital Foundation Board

Will You Join Us at the Next Frontier in Cancer Care and Cure?

When cancer touches your life, as it did mine, there's no question that you want the latest and best treatment options for yourself or someone you love. But you don't have to travel to Memorial Sloan-Kettering, MD Anderson, or the Mayo Clinic for world-class care. You'll find it in your own backyard at the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

Washington University physicians at Siteman aren't just applying the latest discoveries — they're making them. They're at the forefront of many exciting new directions for beating cancer. But this complex disease is going to take a lot of time, dollars and effort to cure... especially when it comes to advancing promising ideas that don't yet have the traction to receive federal research grants. That's the inspiration behind the Cancer Frontier Fund.

Money raised by the Cancer Frontier Fund will promote innovation and collaboration among Siteman's superstars and up-and-coming researchers alike so that bold ideas can turn into clinical applications more quickly. We're offering a new avenue for fueling the brilliant minds, vast knowledge and exceptional technology that keeps Siteman at the leading edge of global cancer centers. For us, our kids and our grandkids, this means a better chance for beating cancer.

Every dollar given to the Cancer Frontier Fund also stays in St. Louis. As we invest these dollars into the Siteman Cancer Center, we'll create jobs, retain the best researchers, draw more patients regionally and nationally, and enhance Siteman's reputation as a top center for cancer treatment, research, discovery and cures. Your gifts to the Cancer Frontier Fund will feed the strength of this community and bolster the local economy.

In 2009, my wife Amy and I worked with the leadership of Barnes-Jewish Hospital and Washington University School of Medicine to develop the concept for the Cancer Frontier Fund, in the hope that it would ultimately inject \$50 to \$100 million into innovative cancer research at Siteman. We cannot do it alone. Many individuals gave our dream momentum by making major gifts last year totaling more than \$1.4 million, and we are grateful for that. We look forward to raising that bar even higher this year at the *illumination10* gala to benefit the




Craig Lockhart, MD, medical oncologist, is one of the first recipients of support from the Cancer Frontier Fund for his work in developmental therapeutics.

Cancer Frontier Fund. But your gift does not need to have a lot of zeroes at the end to be welcome. Imagine the huge impact if 50,000 people gave \$50 each to the Cancer Frontier Fund (and you can do it instantly by visiting the Cancer Frontier Fund page at www.givingbarnesjewish.com). That adds up to \$2.5 million!

St. Louis is a generous community where we have great faith in our medical community to promote our health. I truly believe that the Siteman Cancer Center is the best game in town, and I'm glad to be in a position to give back — and to invite others to give back — to keep it that way and to help it continue its ascent among the elite around the world. When you think of giving for cancer research...when you think of speeding up the pace for cures...when you think of supporting world-class care...I want you to think of the Siteman Cancer Center and the Cancer Frontier Fund.

Join us at www.barnesjewish.org/giving/cancer.

A photograph of a young Black woman with short dark hair, wearing a blue dress with a large floral pattern, laughing heartily while looking at an older woman with white hair. The older woman is seen from the side, wearing a light blue shirt. They are in a bright, indoor setting with a green door visible in the background.

“To laugh often and much ... to win the respect of intelligent people and the affection of children ... to leave the world a better place ... to know even one life has breathed easier because you have lived. This is to have succeeded.”

— *Ralph Waldo Emerson*

BARNES JEWISH
Hospital Foundation
BJC HealthCare

To learn more about giving to Barnes-Jewish Hospital, please call David Sandler at **314-362-3499**, e-mail givingbarnesjewish@bjc.org, or visit www.givingbarnesjewish.org.